Bortezomib
16 NDCs across 14 manufacturers|15 Generic,1 Brand
Bortezomib is used to treat mantle-cell lymphoma and multiple myeloma, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on May 13, 2003, and the first generic was approved May 2, 2022. In 2024, Medicare Part D spent $4 million on Bortezomib across 4,461 claims for 755 beneficiaries.
Bortezomib is available as 16 NDCs from 14 manufacturers (15 generic, 1 brand), with NADAC prices from $43.35 to $1508.21 per EA — the most expensive product costs about 35× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
16
15G / 1B
Manufacturers
14
competing in market
Price Spread
$43.35 – $1508.21
per EA
7d Activity
avg +0.0% WoW · of 16 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
BluePoint Laboratories manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Proteasome Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
14 manufacturers producing BORTEZOMIB(1 pricing outlier)
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
VELCADE 3.5 MG VIAL | $1508.2109 per EA | — |
BORTEZOMIB 3.5 MG VIAL | $43.3460 per EA | — |
BORTEZOMIB 3.5 MG VIAL | $43.3460 per EA | — |
BORTEZOMIB 3.5 MG VIAL | $43.3460 per EA | — |
BORTEZOMIB 3.5 MG VIAL | $43.3460 per EA | — |
BORTEZOMIB 3.5 MG VIAL | $43.3460 per EA | — |
BORTEZOMIB 3.5 MG VIAL | $43.3460 per EA | — |
BORTEZOMIB 3.5 MG VIAL | $43.3460 per EA | — |
BORTEZOMIB 3.5 MG VIAL | $43.3460 per EA | — |
BORTEZOMIB 3.5 MG VIAL | $43.3460 per EA | — |
BORTEZOMIB 3.5 MG VIAL | $43.3460 per EA | — |
BORTEZOMIB 3.5 MG VIAL | $43.3460 per EA | — |
BORTEZOMIB 3.5 MG VIAL | $43.3460 per EA | — |
BORTEZOMIB 3.5 MG VIAL | $43.3460 per EA | — |
BORTEZOMIB 3.5 MG VIAL | $43.3460 per EA | — |
BORTEZOMIB 3.5 MG VIAL | $43.3460 per EA | — |
Frequently Asked Questions
What is Bortezomib used to treat?
Bortezomib is used to treat mantle-cell lymphoma and multiple myeloma, per the National Library of Medicine's MED-RT classification.
When did Bortezomib become available as a generic?
FDA approved the first generic Bortezomib (ANDA) on May 2, 2022.
How much does Medicare spend on Bortezomib?
In 2024, Medicare Part D spent $4 million on Bortezomib across 4,461 claims for 755 beneficiaries.
How many Bortezomib products are on the market?
The Bortezomib drug market contains 16 NDCs from 14 manufacturers — 15 generic and 1 brand product.
What is the price range for Bortezomib?
NADAC reference prices for Bortezomib range from $43.3460 to $1508.2109 per EA — the most expensive product costs about 35× the cheapest.
Is generic Bortezomib cheaper than brand?
The average generic NADAC for Bortezomib is $43.3460 per EA, versus $1508.2109 for brand-labeled products — brand versions average about 35× the generic price.
Which manufacturers make Bortezomib?
14 manufacturers list Bortezomib in NADAC. Ranked by number of NDCs, the largest are BluePoint Laboratories (3), Takeda Pharmaceuticals America, Inc. (1), Zydus Pharmaceuticals (USA) Inc. (1), Meitheal Pharmaceuticals Inc. (1), Hospira Inc. (1).